ExploreWatchlistsPricing
  1. US-listed companies
  2. Atara Biotherapeutics, Inc.
  3. Financials
  4. Stock-based compensation

Atara Biotherapeutics, Inc. (ATRA)

Market cap
$27.72M
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 202427-40.51%
Dec 31, 202345-15.70%
Dec 31, 202254-0.05%
Dec 31, 202154+4.90%
Dec 31, 202051-0.67%
Dec 31, 201952+52.87%
Dec 31, 201834+46.39%
Dec 31, 201723+37.63%
Dec 31, 201617+63.73%
Dec 31, 201510+1.49%
Dec 31, 201410

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat